Practice-Changing Guideline & Consensus Updates

The 2026 AHA/ASA guideline replaces the 2018 guideline and its 2019 update, elevating tenecteplase to a co-first-line thrombolytic with alteplase, endorsing imaging-selected thrombolysis out to 9 hours and in wake-up stroke, expanding endovascular thrombectomy to large ischemic cores and basilar occlusion, and reversing intensive glucose and blood-pressure targets.

The BTF 4th Edition revises hyperosmolar, seizure, steroid, ICP-threshold, and sedation guidance most relevant to neuro-ICU pharmacists.

This consensus statement recalibrates diagnostic thresholds, treatment initiation age, and LDL-C goals for children with familial hypercholesterolaemia, expanding the pharmacist's role in early lipid-lowering therapy.

This consensus document reframes heart failure classification, staging, causes, and trajectories, giving pharmacists a standardized vocabulary that directly influences how guideline-directed medical therapy is selected and continued.

This consensus statement synthesizes the fragmentary evidence base for antithrombotic therapy after coronary artery bypass grafting, translating largely extrapolated data into risk-stratified guidance on agent selection, timing, and duration.

The 2026 ACC/AHA/Multisociety guideline introduces lower treatment goals, formal risk equations, and mandates Lp(a) assessment for dyslipidemia pharmacists.

The 2025 AHA/ACC Guideline introduces PREVENT-based CVD risk, new secondary hypertension triggers, and major changes in initial drug therapy for pharmacists managing hypertension.

Major changes in stroke risk assessment, anticoagulant preferences, and DOAC over warfarin guidance will alter daily pharmacist management of AFib patients.

The 2022 AHA/ACC/HFSA guideline redefines heart failure subtypes and updates foundational recommendations for GDMT, SGLT2 inhibitors, and phenotype-directed care.

The 2024 KDIGO guideline for CKD introduces new recommendations for screening, diagnosis, risk stratification, pharmacologic intervention, and bone-mineral disorder, with significant implications for pharmacist monitoring roles.

The ADA's new Obesity Association standards formalize race- and ethnicity-specific BMI thresholds plus waist-based confirmatory measures, reframing obesity diagnosis around adiposity rather than BMI alone.

The ADA's new Obesity Association guideline reframes obesity pharmacotherapy around treating obesity-related diseases rather than weight targets alone, elevates GLP-1RA and dual GIP/GLP-1RA agents to preferred status across multiple comorbidities, and mandates indefinite continuation to prevent weight recurrence.

Introduces expanded diabetes screening and diagnostic recommendations across diverse populations for pharmacy practice.

GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.

The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.

GINA 2021 formalizes ICS-formoterol as the preferred reliever across all adult/adolescent steps and adds new pediatric and Step 5 options.

This targeted guideline update clarifies when to favor hormonal therapy and spironolactone over prolonged antibiotics in female acne patients, with pregnancy-specific and contraceptive counseling implications for pharmacists.

The 2025 ACIP adult schedule features universal and risk-based expansions for pneumococcal, RSV, and polio vaccines, plus product, schedule, and note updates directly relevant to pharmacists.

The 2019 ATS/IDSA CAP guideline introduces major shifts in diagnostic and empiric therapy strategies for adult patients.

The SCCM/ESICM 2026 update adds prehospital and MDR-stratified antimicrobial guidance, elevates prolonged beta-lactam infusion to a strong recommendation, and expands biomarker, hemodynamic, and long-term recovery statements directly relevant to ICU pharmacists.

The 2023 AGS Beers Criteria update introduces significant modifications and new recommendations impacting antihyperglycemics, anticoagulants, anticholinergics, and select drug–disease interactions for older adults.

The strength of recommendation to avoid clopidogrel in CYP2C19 intermediate metabolizers is elevated to strong, and genotype-guided antiplatelet therapy now formally extends to neurovascular indications.

The American College of Rheumatology reframes non-renal SLE management around universal hydroxychloroquine, aggressive glucocorticoid tapering, and earlier immunosuppressive escalation.

The 2025 EULAR rheumatoid arthritis recommendations abandon prognostic-factor stratification after methotrexate failure and endorse less frequent laboratory monitoring after early tolerance, both directly relevant to ambulatory pharmacists managing DMARD regimens and adherence.